40 results about "Breast cancer chemotherapy" patented technology

The invention discloses a preparation method of a tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA. A PEI-PLGA (polyethyleneimine-poly(lactic-co-glycolic acid)) polymer is dissolved in dichloromethane, deionized water is added, the solution is subjected to ultrasonic crushing and emulsified into a homogenous emulsion, vinyl alcohol, hydrophobic taxol and dichloromethane are mixed and added to the emulsion, the mixture is subjected to ultrasonic crushing and emulsified, the emulsion is evaporated, a nanoparticle suspension is obtained, nanoparticle cores coated with taxol are prepared from the nanoparticle suspension, and then, bleaching, stirring and centrifugation are performed. The breast cancer chemotherapeutic drug and nucleic acid are carried into breast cancer tumor cells with high-expression MTDH genes to inhibit cell proliferation and have significant in-vitro and in-vivo tumor targeting. The carrier has clear anti-tumor effects,used carrier materials have high safety, and the carrier has good biocompatibility and biodegradability and has no biotoxicity or immunogenicity. The preparation process is simple, easy to operate, time-saving, energy-saving and suitable for mass production.

This algorithm provides a marker-free approach to establishing the pixel correspondence among the IR images taken at different times, which is the basis for quantitatively characterizing the variation of the heat energy and patterns pixel-wise on a breast surface. The idea is to use the corner points of the heat pattern and the branch points of the skeletons of the heat pattern on the body surface as the initial fiducial points for the longitudinal IR image registration. The Thin-Plate Spline technique is used to model the nonlinear deformation between two IR images taken at two different times. Mutual information between the TPS-transformed image and the target image is employed as the metric quantifying the quality of the longitudinal IR image registration. To optimize the registration, Nelder-Mead simplex method is used to locally modify the pairings of the fiducial points in the source and target IR images to maximize the mutual information.

The invention provides a breast cancer chemotherapy regimen recommendation method based on weighted KNN. The method comprises the following steps that new cases Pa=<a1,a2,...,an> are input; distances between the new cases Pa=<a1,a2,...,an> and all cases Pi=<x1, x2<2>,...,xn,y> in an original case cool are calculated; first k cases are selected from the original case pool according to the distances from small to large; a recommended therapeutic regimen is obtained through calculation. The breast cancer chemotherapy regimen recommendation method based on the weighted KNN has the following advantages that an intelligent recommendation algorithm is introduced in the decision-making process of a breast cancer auxiliary therapeutic regimen, and the efficiency of the whole course of discussion is improved; when the distance between two cases is calculated, the linear correlation is used in combination to serve as a weight of each attribute; in the process of selecting a final recommended regimen from the most similar results, the influences of the distances are considered, and therefore the recommended whole effect is improved.

The invention discloses an application of a cordyceps militaris link extract to preparation of a health-care product or a medicament for prompting leucocyte proliferation of a breast cancer patient. In an extracting method of the cordyceps militaris link extract, water or an ethanol solution is adopted for extracting cordyceps militaris link. As proved by clinical test of a breast cancer chemotherapy patient, the extract has a good effect on prompting the leucocyte proliferation of the chemotherapy patient, and can be used for preparing a health-care food or a medicament for assisting in treating tumors. The invention discloses a novel clinical application of cordyceps militaris link after increase of leucocytes after chemotherapy on the breast cancer patient. The cordyceps militaris link extract plays a positive role in comprehensively utilizing and developing cordyceps militaris link.

Method for the prediction of the response to epirubicin / cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes.

The invention provides an application of miR-218 in preparing a breast cancer chemotherapeutic drug sensitizer, and belongs to the technical field of molecular drugs of breast cancer. According to theapplication of miR-218 in preparing the breast cancer chemotherapeutic drug sensitizer, miR-218 can obviously increase the sensitivity of breast cancer cells to paclitaxel and doxorubicin; in addition, miR218 can target down-regulate the expression of a DAAM1 gene, and inhibit the proliferation and invasion capacity of breast cancer cells by target down-regulating the expression of the DAAM1 gene. Therefore, a nucleic acid sequence is used as a novel small nucleic acid anti-tumor medicament, so that the sensitivity of breast cancer to chemotherapy medicaments can be enhanced, the proliferation and invasion of tumors can be inhibited, and the nucleic acid sequence has a good application prospect.

The invention provides a long non-coding RNA gene marker for diagnosing breast cancer chemotherapy-related myocardial injury. The long non-coding RNA is LINC01471. Through the discovery of the screening of a chip technology, compared with breast cancer patients before chemotherapy, the expression of the LINC01471 can be significantly enhanced in the blood of the patients with myocardial injury after the chemotherapy, and results can be further verified in fluorescence quantitation PCR. The beneficial effects are as follows: a molecular marker for diagnosing the breast cancer chemotherapy-related myocardial injury is provided; and whether the breast cancer patients have myocardial injury can be judged at the early stage of the chemotherapy by detecting the molecular marker, so that corresponding treatment measures can be taken as early as possible, and the possibility of the myocardial injury occurring in the breast cancer patients during treatment can be decreased. Compared with biochemical markers, the provided lncRNA marker has the characteristics of being high in sensitivity and strong in specificity.

The invention provides application of biochanin A in preparing drug for inhibiting proliferation and transfer of breast cancer, and preparing breast cancer chemotherapy sensitizer. The compound involved in the invention has the effect of reducing ZEB1 gene expression in breast cancer, and further inhibiting the proliferation, transfer and chemotherapy resistance of the breast cancer; biochanin A shows strong breast cancer inhibiting effect and chemotherapy sensitizing effect, and thereby proving a new strategy for the treatment of the breast cancer.

The invention discloses a tumor suppressor gene NDRG2 based application for improving breast cancer chemotherapy sensibility. The tumor suppressor gene NDRG2 is transfected into a breast cancer cell through an expression vector or a virus vector, and the result shows that the tumor suppressor gene NDRG2 can improve the breast cancer chemotherapy sensibility and can be applied to preparation of relevant drugs. The NDRG2 prompts a deoxyribonucleic acid (DNA) damage ability of Adr induced p53 wild type breast cancer cells, improves morphology damage of Adr to p53 wild type breast cancer cells, improves a proliferation inhibiting ability of the Adr to the p53 wild type breast cancer cells, improves the breast cancer chemotherapy sensibility which is independent of specific chemotherapy drugs and further prompts apoptosis of the Adr induced p53 wild type breast cancer cells.

The invention provides a marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and an application of the marker. By detecting an expression level of a sugar chain identified by any one or any combination of lectin LCA, GSL-II, GSL-I, PHA-E+L, WFA and RCA120, whether chemotherapy has a curative effect on a patient subjected to breast cancer chemotherapy or not can be evaluated. The specific basis can be referred to as follows: down regulation is performed on the GSL-II, and a down-regulated Fold-change value is between 0.5 and 1.9; the LCA, the GSL-I andthe RCA120 are up-regulated, and an up-regulated Fold-change value is between 1.68 and 2.4, between 3 and 12.5, and between 0.67 and 2.61; and if PHA-E+L and WFA have no significant difference from ahealthy female control group, then the situation indicates that a curative effect is achieved.

The invention relates to the field of biological medicines, in particular to interference RNA for inhibiting the Rac1 expression and an application thereof in increasing the chemosensitivity to breastcancer, and also discloses a breast cancer chemotherapeutic drug. The invention comprises the interference RNA for inhibiting the Rac1 expression and the chemotherapeutic drug, and a carrier of tumormicroenvironment response for transporting the interference RNA and the chemotherapeutic drug. According to the invention, an acid-sensitive nano-material is used as the carrier, can efficiently convey the siRNA and the chemotherapeutic drug into tumor cells, has a long circulation time in blood, and has high enrichment amount in tumors. Meanwhile, the nano-material encapsulates the siRNA and thechemotherapeutic pro-drug, can effectively silence the target gene and effectively inhibit the expression of drug-resistant genes, enhances the killing effect on tumor cells at the same time, obviously improves the tumor chemotherapy effect, has small toxic and side effects on normal tissue cells, and has no obvious damage to important organs such as heart and liver.

The invention discloses an acupoint patch capable of strengthening the spleen and stomach and a preparation method of the acupoint patch and relates to the technical field of traditional Chinese medicine patches. The acupoint patch is prepared from traditional Chinese medicines including fructus perillae, fructus evodiae, rhizoma pinelliae, pericarpium citri reticulatae, fructus schisandrae, caulis polygoni multiflori and semen ziziphi spinosae. The preparation method of the acupoint patch comprises the following steps: (1) weighing all the raw materials in parts by weight; (2) grinding the fructus perillae, the fructus evodiae, the rhizoma pinelliae, the pericarpium citri reticulatae, the fructus schisandrae, the caulis polygoni multiflori and the semen ziziphi spinosae into powder; (3) squeezing fresh ginger to obtain fresh ginger juice; (4) uniformly stirring the powder in step (2) with the fresh ginger juice in step (3) and water according to the weight proportion of 100 to (1 to 10) to (30 to 50); uniformly coating stirred medicine paste in a medical patch groove to obtain the acupoint patch. The acupoint patch disclosed by the invention has simple components, but also has a remarkable medicinal effect; effective components can be completely absorbed through skin pores and the acceptability of patients is strong. When the application time is long, no allergic phenomenon occurs and medicines remained on skins are easy to wash; the attachment property is strong. The acupoint patch disclosed by the invention is used for treating gastrointestinal reaction caused by breastcancer chemotherapy; the immunity is improved, the clinical effect is remarkable and the acupoint patch is worthy of being affirmed.

The invention discloses an analytic kit for breast cancer chemotherapy. The kit comprises a flow cytometry detection kit, a tissue immunohistochemical detection kit and a real-time fluorescent quantitative PCR detection kit, wherein the flow cytometry detection kit is used for counting the number of cells of a clinical tissue sample after chemotherapy of a breast cancer patient to obtain a first drug resistance assessment coefficient of the breast cancer patient after chemotherapy; the tissue immunohistochemical detection kit is used for performing double staining on the clinical tissue sampleto obtain a second drug resistance assessment coefficient of the breast cancer patient after chemotherapy; performing quantitative amplification for the clinical tissue sample with a real-time fluorescent quantitative PCR detection kit to obtain a third drug resistance assessment coefficient of the breast cancer patient after chemotherapy; and calculating the drug resistance index of the breast cancer patient after chemotherapy through the first drug resistance assessment coefficient, the second drug resistance assessment coefficient and the third drug resistance assessment coefficient. By adopting the method, the product support is provided for comprehensive and complement assessment on the drug resistance situation of the breast cancer patient after chemotherapy.

The invention relates to a medicine delivery system for combined precise treatment of breast cancer and application thereof. Ferroferric oxide is used as a magnetic ligand; meso-porous silicon-graphene nano-sheets are used as basic carriers; medicine delivery carriers are obtained through hydrophilic polymers of polyethylene glycol; the medicine delivery carriers and an insoluble micromolecular chemotherapeutic medicine of adriamycin form a meso-porous silicon-graphene nano-sheet-ferroferric oxide-polyethylene glycol / adriamycin medicine delivery system. The system can be used for the combinedprecise treatment (combining chemotherapy and photothermal therapy) of the breast cancer; the death rate of the breast cancer cells can be obviously improved. Compared with the medicine delivery system built by the prior art, the medicine delivery system has the advantages that various advantages are integrated; the combined targeted treatment of the breast cancer chemotherapy and photothermal therapy can be realized; the toxic and side effects of the whole body can be reduced; the repeated and complicated medicine delivery can be avoided through good medicine release features; the complianceof patients is improved.

The invention discloses a traditional Chinese medicine preparation for preventing toxic and side effects caused by breast cancer chemotherapy. According to traditional Chinese medicine, toxicity of chemical drugs belongs to heat toxin, is likely to convert into fire and harm yin, impairs healthy qi, consumes essence, qi and blood and harms spleen and kidney. Traditional Chinese medicines comprising smilax riparia, hovenia acerba, cyperus difformis, radix clematidis argentilucidae, stahlianthus involucratus, begonia yunnanensis levl, euonymus oxyphyllus, snakeroots, ardisia mamillata hance, Chinese siphonostegia herbs and coral ardisia leaves are decocted with water into decoction. A clinical test shows that the curative effect is remarkably better than that of a contrast group.

The invention relates to two single-nucleotide polymorphism (SNP) sites rs2420946 and rs2981578 associated with a breast cancer on a fibroblast growth factor receptor (FGFR) gene for predicting breast cancer chemotherapy toxicity. Through development and application of an SNP biomarker and a breast cancer chemotherapy toxicity diagnosis kit, the toxicity reaction degree after breast cancer chemotherapy is predicted, thereby guiding medication for tumor chemotherapy and providing a new way for a clinical doctor for predicting prognosis of a patient.

The invention discloses an application of SNP (single nucleotide polymorphism) in the field of breast cancer chemotherapy drug resistance detection and a detection kit of breast cancer chemotherapy drug resistance, and belongs to the technical field of biological medicine. The SNP is an SNP locus rs9344 of a CCND1 gene and / or an SNP locus rs33954691 of a TERT gene. The detection kit of breast cancer chemotherapy drug resistance comprises a primer pair for detecting an SNP locus rs9344 of a CCND1 gene and / or an SNP locus rs33954691 of a TERT gene, and five primers for detecting the SNP locus rs9344 of the CCND1 gene are shown as SEQ ID NO.1-SEQ ID NO.5, five primers for detecting the SNP locus rs33954691 of the TERT are shown as SEQ ID NO.6-SEQ ID NO.10. The correlation of the rs9344 locuson the CCND1 gene and the rs33954691 locus on the TERT gene with breast cancer chemotherapy drug resistance is discovered for the first time, drug resistance screening is carried out during breast cancer chemotherapy, and the effects of risk early warning and early estimation can be effectively achieved.

The invention discloses a breast cancer chemotherapy period traditional Chinese medicine syndrome differentiation and typing discrimination model, which comprises four syndrome types of liver depression and yin deficiency syndrome, qi and yin deficiency syndrome, spleen deficiency and hemophthisis syndrome and qi stagnation and blood stasis syndrome, and discrimination threshold values. The discrimination threshold values of the four syndrome types are all 22.5. The invention further relates to a system for constructing the traditional Chinese medicine syndrome differentiation type discrimination model in the breast cancer chemotherapy period and a model construction method. According to the invention, traditional Chinese medicine is combined with statistics and big data, the traditional Chinese medicine syndrome differentiation and typing discrimination model in the breast cancer chemotherapy period is constructed, and a model construction method is established. According to the model constructed by the invention, traditional Chinese medicine application of breast cancer chemotherapy is normalized and standardized, and a new mode is provided for research, application and popularization of syndrome differentiation of traditional Chinese medicine.

The invention discloses an early breast cancer chemotherapy period traditional Chinese medicine syndrome differentiation typing system which comprises four syndrome types, namely liver depression yin deficiency syndromes, corresponding syndrome items including dysphoria and irritability, thin and white tongue coating, amnesia, chest and hypochondrium swelling pain, dry mouth, hectic fever, chest and abdominal pain, ostalgia, abdominal distension and chest distress; the corresponding syndrome items of the qi-yin deficiency syndrome include deep pulse, thin and white tongue coating, red tongue, hectic fever, amnesia, dry mouth, pale complexion, soreness and weakness of waist and knees, spontaneous perspiration and ruddy complexion; the corresponding syndrome items of the spleen deficiency and hemophthisis are light white tongue color, white and greasy tongue coating, pale complexion, dry mouth, poor appetite, fine pulse and fat and big tongue; the corresponding syndrome items of the qi stagnation and blood stasis syndrome include ecchymosis on the tongue, cyan and purple mouth and lips, collaterals under the tongue, pulse strings, gloomy complexion, numbness of limbs and dental ulcer. The invention further discloses a construction method and application of the system. The invention provides a theoretical basis for standardized traditional Chinese medicine treatment of early breast cancer chemotherapy period patients, and has a wide application prospect.

The invention relates to an external traditional Chinese medicine composition for eliminating breast cancer chemotherapy reaction.The composition is prepared from, by weight, 10-20 g of herba dendrobii, 10-20 g of cortex phellodendri, 15-20 g of radix semiaquilegiae, 10-20 g of radix trichosanthis, 15-20 g of herba portulacae, 10-15 g of semen raphani, 10-15 g of radix ophiopogonis, 10-15 g of concha arcae, 5-10 g of ginger processed pinellia, 5-10 g of radix aucklandiae and 5-10 g of exocarpium citri grandis.The natural traditional Chinese medicine raw materials are adopted and ground into powder to be applied on the umbilical region, has effects on clearing away heat and toxic materials, regulating qi and loosening the center, tonifying stomach and promoting body fluid secretion, tonifying spleen and promoting digestion, relieving hyperacidity and stopping pain, softening hardness to dissipate stagnation, warming the center and removing stasis, and lowering the adverse flow of qi and preventing vomiting, is safe to use, lasting in function, easy and convenient to prepare, wide in medicine source, low in cost, remarkable in treatment effect and mild in medicine property and has the effective rate of 93.3%.

The invention relates to a chemotherapy composition, a preparation method thereof and breast cancer chemotherapy application thereof. The composition is characterized in that the toxicity is small, the anti-cancer activity is high, the composition is mainly composed of a ginsenoside component, a ginseng polysugar component and ifosfamide according to a certain ratio, and the weight ratio is (1-10):(1-10):(1-10). Compared with ifosfamide, the composition has higher anti-cancer activity on experimental breast cancer mice and is almost free of adverse reactions such as myelosuppression.

The invention relates to a marker and a model for predicting chemotherapy response of triple negative breast cancer. The marker comprises one or a combination of more than two of the following genes: AKT2, ARG1, BIRC7, CCR3, CDKN2A, CHGB, CNN1, CYP7A1, FGF5, KMT2A, NME1, NRAS, PCP4, PRC1, PRKCI, SUZ12, VEGFC, WRN and ZBTB16. According to the method, the chemotherapy response is taken as a target function, and the accurate model for predicting the chemotherapy response of the triple-negative breast cancer is established by utilizing the whole transcriptome data of the triple-negative breast cancer slice based on an iterative linear regression algorithm of correlation coefficient layering. By utilizing the model, evaluation can be performed before chemotherapy of a triple-negative breast cancer patient, and the model is used for guiding establishment of a treatment scheme.

The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.

The invention discloses application of an IL-6R inhibitor and IL-4R inhibitor combined drug in breast cancer chemotherapy drugs. IL-4 participates in promoting macrophage M2 polarization, IL-6 is a multi-effect cell factor with wide functions, and IL-4 and IL-6 participate in regulating growth and differentiation of various cells, have the functions of regulating immune response, acute phase reaction and hematopoiesis and play an important role in anti-infection immune response of the body. In the tumor microenvironment, IL-4 and IL-6 participate in promoting macrophage polarization, IL-4 andIL-6 synergistically act in the later stage of tumor development to promote macrophage M2 polarization, and IL-4 and IL-6 have an anti-inflammatory effect and can promote tumor development. The effectof the IL-6R inhibitor and IL-4R inhibitor combined drug in the breast cancer chemotherapy drugs is researched through the synergistic effect of the IL-6R inhibitor and IL-4R inhibitor.

The invention provides a compound taxus chinensis capsule, a preparation method and application of the compound taxus chinensis capsule for treating qi deficiency and phlegm stasis in breast cancer chemotherapy. Wherein the compound taxus chinensis capsule is prepared by mixing a taxus chinensis extract, a red ginseng extract and a liquorice extract. The preparation method adopts a supercritical extraction method. Technical improvement is carried out on the basis of an existing variety, and the technically improved compound taxus chinensis capsule has remarkable activity in maintenance treatment of stable recurrence rejection and / or metastatic advanced triple-negative breast cancer after first-line chemotherapy for 6-8 cycles and drug resistance (qi deficiency and phlegm stasis) of endocrine treatment with positive hormone receptors, and the existing technical blank is filled.